Surface display on lactic acid bacteria without genetic modification: strategies and applications

Mao, Ruifeng; Wu, Dongli; Wang, Yefu

doi:10.1007/s00253-016-7842-8

Cited by 31 publications

(24 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lactic acid bacteria (LAB), particularly their cell surface, have been subject of major interest in various fields of applied research including medicine, food science and biotechnology ( Leenhouts et al 1999 ; Mao et al 2016 ; Michon et al 2016 ). This is primarily because of the combined benefits of organisms offering pro-/pre-biotic effects and generally regarded as safe (GRAS) status ( Klaenhammer et al 2005 ; Wedajo 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Lipoteichoic acid mediates binding of a Lactobacillus S-layer protein

Bönisch

Anzengruber

et al. 2018

Glycobiology

View full text Add to dashboard Cite

The Gram-positive lactic acid bacterium Lactobacillus buchneri CD034 is covered by a two-dimensional crystalline, glycoproteinaceous cell surface (S-) layer lattice. While lactobacilli are extensively exploited as cell surface display systems for applied purposes, questions about how they stick their cell wall together are remaining open. This also includes the identification of the S-layer cell wall ligand. In this study, lipoteichoic acid was isolated from the L. buchneri CD034 cell wall as a significant fraction of the bacterium’s cell wall glycopolymers, structurally characterized and analyzed for its potential to mediate binding of the S-layer to the cell wall. Combined component analyses and 1D- and 2D-nuclear magnetic resonance spectroscopy (NMR) revealed the lipoteichoic acid to be composed of on average 31 glycerol-phosphate repeating units partially substituted with α-d-glucose, and with an α-d-Galp(1→2)-α-d-Glcp(1→3)−1,2-diacyl-sn-Gro glycolipid anchor. The specificity of binding between the L. buchneri CD034 S-layer protein and purified lipoteichoic acid as well as their interaction force of about 45 pN were obtained by single-molecule force spectroscopy; this value is in the range of typical ligand–receptor interactions. This study sheds light on a functional implication of Lactobacillus cell wall architecture by showing direct binding between lipoteichoic acid and the S-layer of L. buchneri CD034.

show abstract

Section: Introductionmentioning

confidence: 99%

Lipoteichoic acid mediates binding of a Lactobacillus S-layer protein

Bönisch

Anzengruber

et al. 2018

Glycobiology

View full text Add to dashboard Cite

show abstract

“…Genetic engineering of LAB has enabled their application to the expression of recombinant proteins. The most common genera used here are Lactococcus and Lactobacillus [124,125]. Metabolic engineering of LAB allows modification of the existing metabolic pathways to improve the properties of LAB as food fermentation starters [126].…”

Section: Genetically Modified Lactic Acid Bacteria As Cell Factoriesmentioning

confidence: 99%

Safety Aspects of Genetically Modified Lactic Acid Bacteria

Plavec

Berlec

2020

Microorganisms

View full text Add to dashboard Cite

Lactic acid bacteria (LAB) have a long history of use in the food industry. Some species are part of the normal human microbiota and have beneficial properties for human health. Their long-standing use and considerable biotechnological potential have led to the development of various systems for their engineering. Together with novel approaches such as CRISPR-Cas, the established systems for engineering now allow significant improvements to LAB strains. Nevertheless, genetically modified LAB (GM-LAB) still encounter disapproval and are under extensive regulatory requirements. This review presents data on the prospects for LAB to obtain ‘generally recognized as safe’ (GRAS) status. Genetic modification of LAB is discussed, together with problems that can arise from their engineering, including their dissemination into the environment and the spread of antibiotic resistance markers. Possible solutions that would allow the use of GM-LAB are described, such as biocontainment, alternative selection markers, and use of homologous DNA. The use of GM-LAB as cell factories in closed systems that prevent their environmental release is the least problematic aspect, and this is also discussed.

show abstract

“…Containing a short peptide linker between two chains of insulin, SCI-57[ 88 ] and SCI-59[ 89 ] were successfully secreted in L. lactis , respectively, retaining their insulin receptor-binding ability. Apart from the genetically modified LAB, non-living LAB bacterium-like particles (BLPs), which perform less anti-carrier response when administrated orally, have been applied as immunostimulants and/or mucosal vaccine delivery vehicles[ 90 ]. Oral feeding with BLPs-SCI-59, in which the above SCI-59 is bound to LAB BLPs in a non-covalent manner, could suppress the process of autoimmune diabetes in NOD mice by restoring the Th1/Th2 imbalance and enhancing Tregs proportions[ 91 ].…”

Section: Oral Tolerance In T1dmmentioning

confidence: 99%

Type 1 diabetes mellitus and its oral tolerance therapy

Mao

Chen

Zhang

et al. 2020

WJD

View full text Add to dashboard Cite

As a T cell-mediated autoimmune disease, type 1 diabetes mellitus (T1DM) is marked by insulin defect resulting from the destruction of pancreatic β-cells. The understanding of various aspects of T1DM, such as its epidemiology, pathobiology, pathogenesis, clinical manifestations, and complications, has been greatly promoted by valuable research performed during the past decades. However, these findings have not been translated into an effective treatment. The ideal treatment should safely repair the destroyed immune balance in a long-lasting manner, preventing or stopping the destruction of β-cells. As a type of immune hypo-responsiveness to the orally administrated antigen, oral tolerance may be induced by enhancement of regulatory T cells (Tregs) or by anergy/deletion of T cells, depending on the dosage of orally administrated antigen. Acting as an antigen-specific immunotherapy, oral tolerance therapy for T1DM has been mainly performed using animal models and some clinical trials have been completed or are still ongoing. Based on the review of the proposed mechanism of the development of T1DM and oral tolerance, we give a current overview of oral tolerance therapy for T1DM conducted in both animal models and clinical trials.

show abstract

Surface display on lactic acid bacteria without genetic modification: strategies and applications

Cited by 31 publications

References 146 publications

Lipoteichoic acid mediates binding of a Lactobacillus S-layer protein

Lipoteichoic acid mediates binding of a Lactobacillus S-layer protein

Safety Aspects of Genetically Modified Lactic Acid Bacteria

Type 1 diabetes mellitus and its oral tolerance therapy

Contact Info

Product

Resources

About